Skip to main content
13 April 2021
Last updated:
Tuesday 13 April 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

New director at Mission Therapeutics

Wednesday 31 March 2021
Company
Mission Therapeutics Ltd
Appointee Name
Jonathan 
Hepple
Country

United Kingdom

Jonathan Hepple has joined the board of Mission Therapeutics Ltd as a non-executive director following the purchase by Rosetta Capital of a stake in Mission. Dr Hepple is co-founder and partner at Rosetta. Mission is developing drugs targeting the ubiquitin pathway for the treatment of kidney and neurodegenerative diseases and fibrosis. Dr Hepple is also a strategic advisor to Oxford Sciences Innovation. He holds a PhD in cancer research from the University of Cambridge and a bachelor’s degree in biology from the University of Oxford.

Mission Therapeutics announced the appointment on 24 March 2021.

Copyright 2021 Evernow Publishing Ltd

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

René Hoet becomes CSO at Montis Biosciences
Wednesday March 31 2021
Pan Cancer T makes board appointments
Wednesday March 31 2021
Björn Englund appointed CEO at Opterion
Wednesday March 31 2021
Sven Zimmermann joins Inotrem
Wednesday March 31 2021
New director at Mission Therapeutics
Wednesday March 31 2021

© 2021 Evernow Publishing Ltd. Powered by Drupal.